enGene Therapeutics Inc. (ENGN): Depreciation & Amortization

Annual figures by period end, from SEC filings.

$500.0K

Year ended 2025-10-31

$700.0K

Trailing 12 months to 2026-07-31

+35.7%

3-year compound annual growth

2022-10-31 Depreciation & Amortization (USD) 2025-10-31

Period ended	Depreciation & Amortization	Change YoY	Source filing
2025-10-31	$500.0K	+66.7%	2025-12-22, From 2024-11-01
2024-10-31	$300.0K	+50.0%	2025-12-22, From 2023-11-01
2023-10-31	$200.0K	0.0%	2024-12-19, From 2022-11-01
2022-10-31	$200.0K	n/a	2024-01-29, From 2021-11-01

Depreciation & Amortization at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	Depreciation & Amortization	Change YoY
enGene Therapeutics Inc. (ENGN)	2025-10-31	$500.0K	+66.7%
Compass Therapeutics, Inc. (CMPX)	2025-12-31	$276.0K	-53.1%
Agenus Inc (AGEN)	2025-12-31	$10.00M	-25.1%
TScan Therapeutics, Inc. (TCRX)	2025-12-31	$2.90M	-29.3%
Solid Biosciences Inc. (SLDB)	2025-12-31	$1.64M	-33.4%
DBV Technologies S.A. (DBVT)	2025-12-31	$2.99M	+9.8%
Instil Bio, Inc. (TIL)	2025-12-31	$534.0K	-85.2%
MeiraGTx Holdings plc (MGTX)	2025-12-31	$12.54M	-2.2%
Neumora Therapeutics, Inc. (NMRA)	2025-12-31	$208.0K	-67.0%

Compare ENGN, CMPX, AGEN, TCRX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗